Novel treatment options in the severe beta-globin disorders.
Molecular Hematology Section, NIDDK, National Institutes of Health, Bethesda, Maryland, USA.
G P
GP
Rodgers
E A
EA
Rachmilewitz
D004921:Erythropoietin / Q000627:therapeutic use; D005232:Fatty Acids, Volatile / Q000627:therapeutic use; D015316:Genetic Therapy; D005914:Globins; D006453:Hemoglobinopathies / Q000628:therapy*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use
D005232:Fatty Acids, Volatile; D004921:Erythropoietin; D005914:Globins; D006918:Hydroxyurea